Thus, there is an urgent need to explore the mechanisms underlying the resistance to BRAF inhibitors in BRAF-mutant thyroid cancers and develop effective strategies to improve their sensitivity to BRAF inhibitors. This evidence concerns the gene BRAF and thyroid gland carcinoma.